Crystalys Therapeutics raised $130 million to support pivotal testing for its gout drug dotinurad, a molecule in late-stage work for an inflammatory disease with limited options. The funding is directed at advancing the program through key confirmatory studies. The report notes dotinurad’s mechanism aligns with a comparable compound Sobi added to its pipeline through a prior $950 million acquisition, suggesting competitive interest in targeting the same or closely related biological axis in gout management. — Key takeaway: the capital infusion signals continued backing for urate/inflammation biology assets as sponsors push toward registrational milestones.